Carfilzomib Triplet Fails to Induce Superior PFS in Newly Diagnosed Multiple Myeloma.

Carfilzomib (Kyprolis) combined with lenalidomide (Revlimid) and dexamethasone (KRd) failed to improve progression-free survival (PFS), compared with the current standard-of-care triplet of bortezomib (Velcade), lenalidomide, and dexamethasone (VRd), in patients with newly diagnosed multiple myeloma (NDMM), according to results of the ENDURANCE trial presented as part of the 2020 American Society of Clinical Oncology Virtual Scientific Program.